Phase II Trial Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk (MDS) Myelodysplastic Syndrome Resistant or Relapsing After ESA Agents (LODEFI)
Phase of Trial: Phase II
Latest Information Update: 14 May 2018
Price : $35 *
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms LODEFI
- 04 May 2018 Status changed from not yet recruiting to recruiting.
- 09 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
- 08 Jan 2018 Planned primary completion date changed from 2 Dec 2017 to 1 Jan 2020.